Neoplasms

Blood and Lymph Conditions

All Conditions

Symptoms and General Pathology

Immune System Diseases

Rare Diseases

Leukemia

Leukemia, Myeloid

Preleukemia

Myelodysplastic Syndromes

Hematologic Neoplasms

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Graft vs Host Disease

Syndrome

Neoplasms by Histologic Type

Hematologic Diseases

Myeloproliferative Disorders

Bone Marrow Diseases

Chronic Disease

Disease Attributes

Precancerous Conditions

Myeloid Leukemia

Chronic Graft Versus Host Disease

Chronic Myeloid Leukemia

Homologous Wasting Disease

Acute Graft Versus Host Disease

Chronic Myeloproliferative Disorders

There will be six cohorts of three patients each. Three escalating doses of MultiStem will be evaluated.

There will be six cohorts of three patients each. Four dosing regimens will be evaluated,varying doses at three times weekly or five times weekly.

Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.

MultiStem®

Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®

Richard Maziarz, MD

Steven Devine, MD

Hillard Lazarus, MD

The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.

Graft-vs.-Host Disease (GVHD) is one of the major limitations of allogeneic hematopoietic stem cell transplants (HSCT). This complication is major cause of morbidity and mortality and is thought to be initiated by activation of donor T-cells through recognition of "foreign" cells resident in the transplant recipient. Acute GVHD is associated with damage to the liver, skin, gastrointestinal tract and mucosa. Moderate to severe GVHD Grades II-IV occurs in 30-50% of matched related HSCTs and 50-70% of unrelated donor recipients. Severe GHVD requires intense immunosuppression involving steroids and additional agents to get it under control, and patients may develop severe infections as a result of such immunosuppression. An agent or cell therapy that could reduce the incidence and/or severity of GVHD without increasing relapse or infectious risk in HSCT patients would provide substantial benefits.

Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

A Phase I, Multicenter, Dose-Escalation Trial Evaluating Maximum-Tolerated Dose of Single and Repeated Administration of Allogeneic MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

Cato Research

Healios K.K.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia	NCT00677859	Hematologic Mal...	MultiStem® MultiStem®	18 Years - 65 Years	Healios K.K.
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia	NCT00677859	Hematologic Mal...	MultiStem® MultiStem®	18 Years - 65 Years	Healios K.K.

Spots Global Cancer Trial Database for multistem®

Every month we try and update this database with for multistem® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for multistem®

Every month we try and update this database with for multistem® cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for multistem® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.